关于儿童NMDA受体抗体脑炎治疗国际共识的评述  

Commons on International Consensus Recommendations for the Treatment of Pediatric NMDA Receptor Antibody Encephalitis

作　　者：张童童 葛许华[1] ZHANG Tong-tong;GE Xu-hua(Pediatric Intensive Care Unit,Children’s Hospital of Nanjing Medical University,Nanjing 210008,China)

机构地区：[1]南京医科大学附属儿童医院急诊/重症医学科,南京210008

出　　处：《中国合理用药探索》2022年第3期16-18,共3页Chinese Journal of Rational Drug Use

摘　　要：NMDA受体抗体脑炎(NMDARE)是儿科最常见的自身免疫性脑炎之一,其临床表现因其抗体相关类型而异。NMDARE的治疗机制尚未完全阐明,治疗策略存在较多争议。本文旨在根据《2021国际共识推荐:儿童NMDA受体抗体脑炎的治疗》中相关推荐,对NMDARE治疗作一评述。NMDA receptor antibody encephalitis(NMDARE) is one of the most common autoimmune encephalitis in pediatrics, the clinical manifestations vary with the type of antibody. The therapeutic mechanism of NMDARE have not been fully clarified, and there are many disputes about the treatment strategies. The purpose of this article is to comment on the treatments of NMDARE according to the 2021 International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis.

关 键 词：NMDA受体抗体脑炎 国际共识 儿童 治疗 利妥昔单抗 

分 类 号：R720.5[医药卫生—儿科]